Nebacumab: Difference between revisions
m Protected "Nebacumab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
Kiran Singh (talk | contribs) No edit summary |
||
Line 25: | Line 25: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__Notoc__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Nebacumab''' is a [[human]] [[monoclonal antibody]] and which it is used to treat bacterial infections. | '''Nebacumab''' is a [[human]] [[monoclonal antibody]] and which it is used to treat bacterial infections. | ||
==References== | |||
{{Reflist|2}} | |||
{{monoclonal-antibody-stub}} | {{monoclonal-antibody-stub}} | ||
{{Humanmonoclonals}} | {{Humanmonoclonals}} |
Latest revision as of 17:46, 15 April 2015
WikiDoc Resources for Nebacumab |
Articles |
---|
Most recent articles on Nebacumab |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Nebacumab at Clinical Trials.gov Clinical Trials on Nebacumab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Nebacumab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Nebacumab Discussion groups on Nebacumab Directions to Hospitals Treating Nebacumab Risk calculators and risk factors for Nebacumab
|
Healthcare Provider Resources |
Causes & Risk Factors for Nebacumab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Nebacumab is a human monoclonal antibody and which it is used to treat bacterial infections.